ACL retweeted
New publication🚨
Here we synthethized available evidence on the use of low-doses of nivolumab for r/r HL, an alternative not-so-rarely used in LMICs
@PerlaRcp
ascopubs.org/doi/pdf/10.120…
ACL retweeted
2nd day of preceptorship on lymphomas today! @HopSaintLouis @muséedesmoulages.
Toxicities of #cartcell , #nuclearmedicine challenges, pharmacological features and more!
Welcome 🇲🇽! @RenataUrsu @laetitiavercellino @c_thieblemont @isabellemadelaine @CCristinelli
ACL retweeted
"No, yo nunca dije que iba a retirar al Ejército"
¡Veamos qué dice el mentirómetro!
#SátiraSurrealista de @vampipe
#Latinus #InformaciónParaTi
Effect of PEEP on the lungs @JustinKrantz
ACL retweeted
Man City finally winning the Champions League is such a fairytale story. Amazing what can be achieved with over £2 billion spent in transfers, a manager with an offshore account, a suspended 2 year ban from European competitions and 115 charges of financial irregularity.
ACL retweeted
#HematoTime
Dr. Adrián Alejandro Ceballos López
Daratumumab, lenalidomida y dexametasona mejoran la supervivencia de pacientes con MM R/R sin tratamiento previo con un anticuerpo monoclonal.
bit.ly/3WxfNZ2
ACL retweeted
F1 para dummies 2023:
Max Verstappen:
- Campeón los últimos 2 años
- Famoso por quitarle la novia a Kvyat, el octavo campeonato a Hamilton, la ilusión a los fans de Ferrari y la esperanza a los fans de Checo Perez
- En México lo odian por no dejar pasar a Checo en Brasil 2022
Reduced Venetoclax Exposure With Azacitidine Appears Feasible in Treatment-Naïve AML ashpublications.org/ashclini…
7+7 instead of 7+28, similar results
@GomezDLeonMD @dgomezalmaguer
O sea, a esperar que se recuperen del 7+3
This Post is from an account that no longer exists. Learn more
ACL retweeted
The refs are calling a flag on the 49ers EVERY SINGLE PLAY. Remember when they said Vegas specifically said they wanted the 49ers to lose.
ACL retweeted
The fact that Ndamukong Suh wasn’t called for roughing the passer after landing with all his body weight says it all
Auto-TMO vs ibrutunib en Linfoma del Manto en pacientes aptos para TMO. Interesante será ver las toxicidades a corto, mediano y largo plazo.
ACL retweeted
Nuestro póster presentado en #AMEH22 es eL 1er estudio de análisis mutacional en #LLC #CLL con resultados interesante como 58% de IgVH no mutados. Los esperamos en la tarde. Póster LCR0007. @ContactoAmeh





























